Probiotics Interactions

Live probiotic bacteria can translocate across the gut wall and cause bacteremia, endocarditis, or sepsis in patients whose immune systems are pharmacologically suppressed (e.g., calcineurin inhibitors, mTOR inhibitors, corticosteroids, mycophenolate). Multiple case reports document Lactobacillus and Bifidobacterium bloodstream infections in solid-organ and stem-cell transplant recipients.

Chemotherapy frequently induces neutropenia and damages the gut mucosa, which together increase the risk that ingested probiotic organisms can translocate into the bloodstream and cause bacteremia, fungemia, or sepsis. Major dietary guidelines for neutropenic cancer patients recommend avoiding probiotic supplements.

Antibiotics kill probiotic bacteria, reducing their effectiveness

Systemic antifungals (fluconazole, itraconazole, amphotericin B, echinocandins) can kill yeast-based probiotics such as Saccharomyces boulardii, reducing their effectiveness. Bacterial probiotics like Lactobacillus and Bifidobacterium are generally unaffected by azole antifungals because their cell structures differ from fungi.

Prebiotics are non-digestible fibers (like inulin, FOS, GOS) that selectively feed beneficial bacteria; combining them with probiotic strains creates a 'synbiotic' that improves colonization, short-chain fatty acid production, and gut barrier function more effectively than either alone.

Vitamin D and probiotics share regulatory pathways: vitamin D supports VDR expression in gut epithelium, which probiotics depend on for anti-inflammatory and barrier effects, while certain probiotic strains modestly raise serum 25(OH)D. Combined supplementation outperforms either alone for inflammatory and gut-barrier endpoints in randomized trials.